


**Product Name** : Mubritinib  
**Cat. No.** : PC-20781  
**CAS No.** : 366017-09-6  
**Molecular Formula** : C<sub>25</sub>H<sub>23</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>  
**Molecular Weight** : 468.47  
**Target** : EGFR  
**Solubility** : 10 mM in DMSO



CAS: 366017-09-6

## Biological Activity

Mubritinib (TAK-165) is a potent inhibitor of human epidermal growth factor receptor 2 (**HER2**, ERBB2) tyrosine kinase with IC<sub>50</sub> of 6 nM, also is a potent **Complex I** inhibitor with IC<sub>50</sub> of 51 nM.

Mubritinib (TAK-165) does not inhibit other types tyrosine kinase up to 25,000 nM.

Mubritinib (TAK-165) inhibits HER2 phosphorylation and its down-stream Akt and MAPK in HER2 strongly expressing cells (BT474 breast cancer cell line).

Mubritinib (TAK-165) shows synergistic effect with trametinib in KRAS-mutant cell lines.

Mubritinib exhibits strong anti-leukemic effects in vitro and in vivo, functions through ubiquinone-dependent inhibition of electron transport chain (ETC) complex I activity.

Mubritinib (TAK-165) inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.

## References

Nagasawa J, et al. *Int J Urol*. 2006 May;13(5):587-92.

Bacelli I, et al. *Cancer Cell*. 2019 Jul 8;36(1):84-99.e8.

Ding Xue, et al. *J Med Chem*. 2022 Jan 13;65(1):343-368.

Uitdehaag JC, et al. *PLoS One*. 2015 May 27;10(5):e0125021.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com